Friday, 13 November 2026European Markets

KLEPIERRE And PATRIMOINE ET COMM Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - klepierre (li.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
klepierre (li.pa) €24.00 7.32% 1.7%
patrimoine et comm (pat.pa) €20.00 6.1% 6.3%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. klepierre (li.pa)

7.32% forward dividend yield and 1.7% return on equity

klépierre sa is the european leader in shopping malls, combining property development and asset management skills. the company's portfolio is valued at €19.3 billion at december 31, 2023, and comprises large shopping centers in more than 10 countries in continental europe which together host hundreds of millions of visitors per year. klépierre sa holds a controlling stake in steen & strøm (56.1%), scandinavia's number one shopping center owner and manager. klépierre sa is a french reit (siic) listed on euronext paris and is included in the cac next 20 and epra euro zone indexes. it is also included in ethical indexes, such as euronext cac 40 esg, euronext cac sbt 1.5, msci europe esg leaders, ftse4good, euronext vigeo europe 120, and features in cdp's “a-list”. these distinctions underscore the group's commitment to a proactive sustainable development policy and its global leadership in the fight against climate change.

earnings per share

as for profitability, klepierre has a trailing twelve months eps of €0.6.

pe ratio

klepierre has a trailing twelve months price to earnings ratio of 40. meaning, the purchaser of the share is investing €40 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.7%.

more news about klepierre.

2. patrimoine et comm (pat.pa)

6.1% forward dividend yield and 6.3% return on equity

patrimoine et commerce sa, a real estate company, engages in the acquisition, development, and operation of commercial real estate properties in france. the company operates a portfolio of 31 real estate assets covering a total area of 129,280 square meters located in high-attraction areas in the suburbs or centers of medium-sized cities. its property portfolio includes shopping malls, supermarkets, shops, and business parks. the company is based in boulogne-billancourt, france.

earnings per share

as for profitability, patrimoine et comm has a trailing twelve months eps of €1.91.

pe ratio

patrimoine et comm has a trailing twelve months price to earnings ratio of 10.47. meaning, the purchaser of the share is investing €10.47 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.3%.

more news about patrimoine et comm.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com